Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion

Massimo Chiariello, Paolo Golino, Maurizio Cappelli-Bigazzi, Giuseppe Ambrosio, Isabella Tritto, Marco Salvatore

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

In this study we attempted to determine whether administration of iloprost (ZK 36374), a chemically stable prostacyclin analogue, would reduce infarct size after experimental coronary artery occlusion and reperfusion. One hour of coronary artery occlusion was performed in 28 open-chest, anesthetized rabbits, followed by 5 hours of reperfusion. Two minutes after occlusion, 99mTc-labeled albumin microspheres were injected into the left atrium for later assessment of the area at risk of infarction. Fifteen minutes after occlusion animals were randomly assigned to either the treatment group (iloprost, 1.2 μg/kg/min intravenously for 6 hours; n = 14) or the control group (n = 14). In vitro platelet aggregation was inhibited in rabbits receiving iloprost. In 10 rabbits (five treated and five control) regional myocardial blood flow was also measured by means of differentially labeled radioactive microspheres. Infarct size was significantly smaller in treated rabbits (53.6 ± 4.1% of the risk zone vs 89.4 ± 3.8% in control rabbits; p <0.001). Flow to the nonischemic myocardium was higher in treated animals, that is, 1.87 ± 0.20 ml/min/gm of tissue 50 minutes after occlusion and 1.90 ± 0.20 ml/min/gm of tissue 4 hours after reperfusion, compared with 1.54 ± 0.20 and 1.64 ± 0.30 ml/min/gm of tissue, respectively, in control rabbits (p <0.01). Collateral flow to the ischemic region was not affected by the drug. Mean arterial blood pressure, heart rate, and pressure-rate product in treated rabbits were not significantly different from values in control rabbits. In conclusion, administration of iloprost reduced myocardial infarct size in this model of myocardial ischemia and reperfusion in absence of major hemodynamic effects.

Original languageEnglish
Pages (from-to)499-504
Number of pages6
JournalAmerican Heart Journal
Volume115
Issue number3
DOIs
Publication statusPublished - 1988

Fingerprint

Iloprost
Coronary Occlusion
Epoprostenol
Reperfusion
Coronary Vessels
Rabbits
Myocardial Reperfusion
Microspheres
Arterial Pressure
Regional Blood Flow
Heart Atria
Platelet Aggregation
Infarction
Myocardial Ischemia
Albumins
Myocardium
Thorax
Heart Rate
Hemodynamics
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion. / Chiariello, Massimo; Golino, Paolo; Cappelli-Bigazzi, Maurizio; Ambrosio, Giuseppe; Tritto, Isabella; Salvatore, Marco.

In: American Heart Journal, Vol. 115, No. 3, 1988, p. 499-504.

Research output: Contribution to journalArticle

Chiariello, Massimo ; Golino, Paolo ; Cappelli-Bigazzi, Maurizio ; Ambrosio, Giuseppe ; Tritto, Isabella ; Salvatore, Marco. / Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion. In: American Heart Journal. 1988 ; Vol. 115, No. 3. pp. 499-504.
@article{7d509ac9952049ad821aa3dd5dc95bcf,
title = "Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion",
abstract = "In this study we attempted to determine whether administration of iloprost (ZK 36374), a chemically stable prostacyclin analogue, would reduce infarct size after experimental coronary artery occlusion and reperfusion. One hour of coronary artery occlusion was performed in 28 open-chest, anesthetized rabbits, followed by 5 hours of reperfusion. Two minutes after occlusion, 99mTc-labeled albumin microspheres were injected into the left atrium for later assessment of the area at risk of infarction. Fifteen minutes after occlusion animals were randomly assigned to either the treatment group (iloprost, 1.2 μg/kg/min intravenously for 6 hours; n = 14) or the control group (n = 14). In vitro platelet aggregation was inhibited in rabbits receiving iloprost. In 10 rabbits (five treated and five control) regional myocardial blood flow was also measured by means of differentially labeled radioactive microspheres. Infarct size was significantly smaller in treated rabbits (53.6 ± 4.1{\%} of the risk zone vs 89.4 ± 3.8{\%} in control rabbits; p <0.001). Flow to the nonischemic myocardium was higher in treated animals, that is, 1.87 ± 0.20 ml/min/gm of tissue 50 minutes after occlusion and 1.90 ± 0.20 ml/min/gm of tissue 4 hours after reperfusion, compared with 1.54 ± 0.20 and 1.64 ± 0.30 ml/min/gm of tissue, respectively, in control rabbits (p <0.01). Collateral flow to the ischemic region was not affected by the drug. Mean arterial blood pressure, heart rate, and pressure-rate product in treated rabbits were not significantly different from values in control rabbits. In conclusion, administration of iloprost reduced myocardial infarct size in this model of myocardial ischemia and reperfusion in absence of major hemodynamic effects.",
author = "Massimo Chiariello and Paolo Golino and Maurizio Cappelli-Bigazzi and Giuseppe Ambrosio and Isabella Tritto and Marco Salvatore",
year = "1988",
doi = "10.1016/0002-8703(88)90796-X",
language = "English",
volume = "115",
pages = "499--504",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion

AU - Chiariello, Massimo

AU - Golino, Paolo

AU - Cappelli-Bigazzi, Maurizio

AU - Ambrosio, Giuseppe

AU - Tritto, Isabella

AU - Salvatore, Marco

PY - 1988

Y1 - 1988

N2 - In this study we attempted to determine whether administration of iloprost (ZK 36374), a chemically stable prostacyclin analogue, would reduce infarct size after experimental coronary artery occlusion and reperfusion. One hour of coronary artery occlusion was performed in 28 open-chest, anesthetized rabbits, followed by 5 hours of reperfusion. Two minutes after occlusion, 99mTc-labeled albumin microspheres were injected into the left atrium for later assessment of the area at risk of infarction. Fifteen minutes after occlusion animals were randomly assigned to either the treatment group (iloprost, 1.2 μg/kg/min intravenously for 6 hours; n = 14) or the control group (n = 14). In vitro platelet aggregation was inhibited in rabbits receiving iloprost. In 10 rabbits (five treated and five control) regional myocardial blood flow was also measured by means of differentially labeled radioactive microspheres. Infarct size was significantly smaller in treated rabbits (53.6 ± 4.1% of the risk zone vs 89.4 ± 3.8% in control rabbits; p <0.001). Flow to the nonischemic myocardium was higher in treated animals, that is, 1.87 ± 0.20 ml/min/gm of tissue 50 minutes after occlusion and 1.90 ± 0.20 ml/min/gm of tissue 4 hours after reperfusion, compared with 1.54 ± 0.20 and 1.64 ± 0.30 ml/min/gm of tissue, respectively, in control rabbits (p <0.01). Collateral flow to the ischemic region was not affected by the drug. Mean arterial blood pressure, heart rate, and pressure-rate product in treated rabbits were not significantly different from values in control rabbits. In conclusion, administration of iloprost reduced myocardial infarct size in this model of myocardial ischemia and reperfusion in absence of major hemodynamic effects.

AB - In this study we attempted to determine whether administration of iloprost (ZK 36374), a chemically stable prostacyclin analogue, would reduce infarct size after experimental coronary artery occlusion and reperfusion. One hour of coronary artery occlusion was performed in 28 open-chest, anesthetized rabbits, followed by 5 hours of reperfusion. Two minutes after occlusion, 99mTc-labeled albumin microspheres were injected into the left atrium for later assessment of the area at risk of infarction. Fifteen minutes after occlusion animals were randomly assigned to either the treatment group (iloprost, 1.2 μg/kg/min intravenously for 6 hours; n = 14) or the control group (n = 14). In vitro platelet aggregation was inhibited in rabbits receiving iloprost. In 10 rabbits (five treated and five control) regional myocardial blood flow was also measured by means of differentially labeled radioactive microspheres. Infarct size was significantly smaller in treated rabbits (53.6 ± 4.1% of the risk zone vs 89.4 ± 3.8% in control rabbits; p <0.001). Flow to the nonischemic myocardium was higher in treated animals, that is, 1.87 ± 0.20 ml/min/gm of tissue 50 minutes after occlusion and 1.90 ± 0.20 ml/min/gm of tissue 4 hours after reperfusion, compared with 1.54 ± 0.20 and 1.64 ± 0.30 ml/min/gm of tissue, respectively, in control rabbits (p <0.01). Collateral flow to the ischemic region was not affected by the drug. Mean arterial blood pressure, heart rate, and pressure-rate product in treated rabbits were not significantly different from values in control rabbits. In conclusion, administration of iloprost reduced myocardial infarct size in this model of myocardial ischemia and reperfusion in absence of major hemodynamic effects.

UR - http://www.scopus.com/inward/record.url?scp=0023915824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023915824&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(88)90796-X

DO - 10.1016/0002-8703(88)90796-X

M3 - Article

C2 - 2449815

AN - SCOPUS:0023915824

VL - 115

SP - 499

EP - 504

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -